Athersys Board News Today

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces changes to its Board of Directors following the Company’s recent 2023 Annual Meeting of Stockholders. Current Director Jane Wasman, JD, has been ap...

Athersys, Inc. , a regenerative medicine company developing MultiStem® for critical care indications, announces changes to its Board of Directors following the Company’s recent 2023 Annual...

Healthcare Executive and Strategy Consultant Brings Considerable Innovation, Commercialization and Entrepreneurial Expertise ...

Athersys Announces Board of Directors Slate for 2022 Annual Meeting of Stockholders and Director Departures - read this article along with other careers information, tips and advice on BioSpace

Annual Meeting of Stockholders rescheduled to Thursday, July 28, 2022, 8:30 a.m. ETCLEVELAND--(BUSINESS WIRE)--$ATHX--Athersys, Inc. (Nasdaq: ATHX) today announced the postponement of its Annual Meeting of Stockholders, initially scheduled for Wednesday, June 15, 2022, at 8:30 a.m. ET. The Annual Meeting is now sche...

Athersys has been focused on developing a viable treatment for stroke for nearly 20 years. Read more to find out if now a good time to buy ATHX stock.

Athersys Reports First Quarter 2021 Results Search jobs Management to host conference call at 4:30 pm EDT today CLEVELAND--(BUSINESS WIRE)--$ATHX#Athersys--Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended March 31, 2021 and provided a corporate update. “Since our recent call, we remain on track with respect to our operating plans,” stated Mr. William (B.J.) Lehmann, Jr., Interim Chief Executive Officer of Athersys. “We look forward to importa...

Press release content from Business Wire. The AP news staff was not involved in its creation. Athersys Announces CEO Transition CLEVELAND, Ohio--(BUSINESS WIRE)--Feb 16, 2021-- Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem ® cell therapy, today announced that Dr. Gil Van Bokkelen has stepped down as Chairman and Chief Executive Officer, effective immediately. The Athersys Board has appointed William (B.J.) Lehmann, the Company’s President and Chief Opera...

Press release content from Business Wire. The AP news staff was not involved in its creation. Athersys Announces Cooperation Agreement With HEALIOS K.K. February 16, 2021 GMT CLEVELAND--(BUSINESS WIRE)--Feb 16, 2021-- Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem ® cell therapy, today announced that it has entered into a cooperation agreement with HEALIOS K.K. (“Healios”), the Company’s largest shareholder and one of its commercial partners, and Dr. ...